Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: A case-control study in a French teaching hospital

Clinical Microbiology and Infection

Volumn 17, Issue 11, 2011, Pages 1746-1751

  Cassier, P ^a   Lallechere S ^a   Aho, S ^a   Astruc, K ^a   Neuwirth, C ^b   Piroth, L ^c   Chavanet, P ^c  

^a Service d'Hygiène et d'Epidemiologie Hospitalière   (France)

^b Lab de Bacteriologie Hygiene   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotic resistance; Case control study; Cephalosporin; CTX M producing Escherichia coli; Fluoroquinolone; lactamase

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TICARCILLIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL FEEDING; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BLADDER CATHETERIZATION; CONTROLLED STUDY; CTX M BETA LACTAMASE PRODUCING ESCHERICHIA COLI; DISEASE ASSOCIATION; DRUG EXPOSURE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; FRANCE; HEMODIALYSIS; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTION; VEIN CATHETERIZATION;

ESCHERICHIA COLI;

EID: 79960941037     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03349.x     Document Type: Article

References (32)

1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: 573-583.
2. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-166.
3. Arlet G, Sanson-le Pors MJ, Rouveau M et al. Outbreak of nosocomial infections due to Klebsiella pneumoniae producing SHV-4 β-lactamase. Eur J Clin Microbiol Infect Dis 1990; 9: 797-803.
4. Briñas L, Lantero M, Zarazaga M, Pérez F, Torres C Outbreak of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in a neonatal-pediatric intensive care unit in Spain. Microb Drug Resist 2004; 10: 354-358.
5. Brigante G, Luzzaro F, Perilli M et al. Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents 2005; 25: 157-162.
6. Pitout JD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents 2008; 32: 333-338.
7. Ruppé E, Hem S, Lath S et al. CTX-M β-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia. Emerg Infect Dis 2009; 15: 741-748.
8. Baudry PJ, Nichol K, DeCorby M et al. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. Diagn Microbiol Infect Dis 2009; 63: 319-326.
9. Soussy CJ. Comité de l'Antibiogramme de la Société Française de Microbiologie Recommandations 2007.
10. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
11. Neuwirth C, Siebor E, Pruneaux M et al. First isolation of CTX-M15-producing Escherichia coli from two French patients. J Antimicrob Chemother 2003; 51: 471-473.
12. Colodner R. Extended-spectrum beta-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005; 33: 104-107.
13. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463.
14. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
15. Yu WL, Chuang YC, Walther-Rasmussen J. Extended-spectrum β-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006; 39: 264-277.
16. Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005; 43: 2844-2849.
17. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000; 14: 137-142.
18. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 2007; 35: 606-612.
19. Ben-Ami R, Rodríguez-Baño J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690.
20. Lavigne JP, Marchandin H, Delmas J et al. CTX-M β-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol 2007; 45: 620-626.
21. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
22. Peña C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35: 9-16.
23. Peña C, Gudiol C, Tubau F et al. Risk-factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 2006; 12: 279-284.
24. Rodriguez-Baño J, Picón E, Gijón P et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50: 40-48.
25. Skippen I, Shemko M, Turton J, Kaufmann ME, Palmer C, Shetty N. Epidemiology of infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 2006; 64: 115-123.
26. Lopez E, Blazquez J. Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in Escherichia coli. Antimicrob Agents Chemother 2009; 53: 3411-3415.
27. López E, Elez M, Matic I, Blázquez J et al. Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Mol Microbiol 2007; 64: 83-93.
28. Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae and associated risk factors. Indian J Med Res 2009; 129: 695-700.
29. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002; 34: 1558-1563.
30. Behar PR, Teixeira PJ, Fachel JM, Kalil AC. The effect of control group selection in the analysis of risk factors for extended spectrum β-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J Hosp Infect 2008; 68: 123-129.
31. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002; 23: 254-260.
32. Rodríguez-Baño J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.